Live Feeds
● TRACKER Updated 19d ago · 7 sources tracked

Moderna’s Cancer Vaccine Gives Stock a New Growth Story. Will It Have a Happy Ending?

Moderna and Merck have developed an mRNA vaccine that prevents melanoma from returning. The treatment represents a shift toward viable cancer vaccinations and has triggered a 14% jump in Moderna stock, pushing the price past $150. Wolfe analysts estimate the cancer-vaccine opportunity is worth $9.2 billion. While the breakthrough suggests a potential wave of similar vaccines for other cancers, experts continue to evaluate the barriers to wide clinical use and the long-term efficacy of the treatment.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna and Merck developed an mRNA vaccine that prevents melanoma from returning.
  • ✓ Moderna stock rose 14% to a price exceeding $150.
🛡️ Source Corroboration: 7 independent reporting domains (80% confidence) ⏱ Read time: ~2 min

What changed

Moderna and Merck reported that their mRNA vaccine successfully prevents melanoma from returning.

Live updates

  1. Moderna and Merck mRNA Vaccine Prevents Melanoma Recurrence

    Moderna and Merck have developed an mRNA vaccine that prevents melanoma from returning. The treatment represents a shift toward viable cancer vaccinations and has triggered a 14% jump in Moderna stock, pushing the price past $150. Wolfe analysts estimate the cancer-vaccine opportunity is worth $9.2 billion. While the breakthrough suggests a potential wave of similar vaccines for other cancers, experts continue to evaluate the barriers to wide clinical use and the long-term efficacy of the treatment.

    Why it matters

    Traditional cancer treatments often struggle with recurrence after primary tumors are removed. This mRNA approach aims to train the immune system to recognize and attack remaining cancer cells. It leverages the same technology used in COVID-19 vaccines to target oncology.

    What is confirmed

    • Moderna and Merck developed an mRNA vaccine that prevents melanoma from returning.
    • Moderna stock rose 14% to a price exceeding $150.

    Still unconfirmed

    • Wolfe sees a $9.2 billion opportunity for cancer vaccines.
    • The breakthrough could lead to a wider wave of various cancer vaccines.

    What to watch next

    • Results from expanded clinical trials regarding other cancer types.
    Sources used for this update (8)
    1. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
    2. CNN — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    3. The Economist — It now seems possible to vaccinate against cancer
    4. The Washington Post — What it was like to go through a trial that could revolutionize cancer treatment
    5. Reuters — The Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use?
    6. Barron's — Moderna’s Cancer Vaccine Gives Stock a New Growth Story. Will It Have a Happy Ending?
    7. Yahoo Finance — MRNA Stock Jumps 14% Past $150 As Wolfe Sees $9.2B Cancer-Vaccine Opportunity
    8. The Washington Post — ‘Science fiction’: Five exciting new medical breakthroughs
    confidence 80%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community